Corcept Profit Jumps To $126.8 Million As New Ovarian Cancer Drug Lifyorli Sells $91.4 Million
Revenue rose 64% to $340.5 million, and the drugmaker held its $1.1 billion to $1.2 billion 2026 revenue forecast.
Corcept Therapeutics, which sells the Cushing's syndrome drug Korlym, said Tuesday that third-quarter revenue rose 64% from a year earlier to $340.5 million, helped by $91.4 million in sales of its new ovarian cancer drug Lifyorli. Net income reached $126.8 million, up from $19.7 million in the third quarter of 2025.
Lifyorli nearly doubles in a quarter
Lifyorli, launched April 1, grew 92% from the second quarter to $91.4 million. Korlym and its authorized generic brought in $249.1 million, up 19% from the second quarter. Total revenue was $256.1 million in the second quarter.
CEO Joseph K. Belanoff said Lifyorli's uptake has been "both very rapid and broad," with more than 2,300 patients treated and more than 1,700 physicians prescribing it. Corcept reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion.
Diluted earnings were $1.01 per share, against $0.16 a year earlier. Net income was $43.0 million in the second quarter.
Spending climbs with the launch
Selling, general and administrative spending rose to $164.4 million from $124.0 million a year earlier. Research and development fell to $56.7 million from $68.8 million. Total operating expenses were $225.7 million, versus $214.8 million in the second quarter.
Cash and investments stood at $662.3 million on September 30, up from $544.6 million at June 30. The company bought back $43.7 million of its stock in the quarter.
A Cushing's decision due December 17
Corcept develops drugs that modulate the hormone cortisol, with Korlym marketed for hypercortisolism, also called Cushing's syndrome. The FDA's target date to rule on its resubmitted application for relacorilant in Cushing's is December 17.
In Europe, the drug regulator's committee recommended in September that relacorilant plus nab-paclitaxel be approved for platinum-resistant ovarian cancer. Corcept expects European Commission approval by year-end.
In the 95-patient BELLA Part A trial, relacorilant added to nab-paclitaxel and bevacizumab produced median progression-free survival of 7.2 months and a 59% response rate. Among patients with no prior bevacizumab, those figures were 8.1 months and 66%.
Corcept said it plans to start a Phase 3 trial in ALS next year, after exploratory analyses of dazucorilant showed an 84% reduction in risk of death in the first year.
